Given that the expression of p-GSK-3β was reduced by the combined therapy, we further established stable NPC cells with either GSK-3β overexpression or knockdown, as confirmed by western blotting (Supplementary Fig. S7A, B, E, F). The gene discussed is GSK3B; the disease is nasopharyngeal carcinoma.